Enzo Biochem Price to Sales Ratio 2010-2022 | ENZ

Historical PS ratio values for Enzo Biochem (ENZ) over the last 10 years. The current P/S ratio for Enzo Biochem as of May 27, 2022 is . For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Enzo Biochem P/S Ratio Historical Data
Date Stock Price TTM Sales per Share Price to Sales Ratio
2022-05-27 2.26 0.93
2022-01-31 3.22 $2.44 1.32
2021-10-31 3.44 $2.39 1.44
2021-07-31 3.26 $2.44 1.34
2021-04-30 3.07 $2.33 1.31
2021-01-31 2.82 $2.02 1.40
2020-10-31 1.82 $1.77 1.03
2020-07-31 2.38 $1.60 1.49
2020-04-30 3.02 $1.63 1.86
2020-01-31 2.51 $1.69 1.49
2019-10-31 3.16 $1.69 1.87
2019-07-31 3.91 $1.71 2.28
2019-04-30 3.47 $1.76 1.97
2019-01-31 3.76 $1.88 2.00
2018-10-31 3.32 $2.03 1.64
2018-07-31 4.42 $2.15 2.06
2018-04-30 6.00 $2.22 2.71
2018-01-31 7.36 $2.26 3.25
2017-10-31 9.85 $2.27 4.33
2017-07-31 10.85 $2.27 4.78
2017-04-30 8.80 $2.29 3.84
2017-01-31 6.68 $2.28 2.93
2016-10-31 6.10 $2.24 2.72
2016-07-31 6.97 $2.22 3.15
2016-04-30 4.98 $2.21 2.25
2016-01-31 4.74 $2.16 2.19
2015-10-31 3.72 $2.15 1.73
2015-07-31 3.00 $2.16 1.39
2015-04-30 2.80 $2.18 1.28
2015-01-31 3.15 $2.21 1.43
2014-10-31 5.22 $2.24 2.33
2014-07-31 4.80 $2.27 2.11
2014-04-30 4.20 $2.28 1.84
2014-01-31 2.81 $2.29 1.22
2013-10-31 2.49 $2.31 1.08
2013-07-31 2.18 $2.38 0.92
2013-04-30 2.24 $2.47 0.91
2013-01-31 2.89 $2.57 1.13
2012-10-31 2.00 $2.65 0.76
2012-07-31 1.50 $2.66 0.56
2012-04-30 2.74 $2.68 1.02
2012-01-31 2.55 $2.68 0.95
2011-10-31 2.86 $2.66 1.08
2011-07-31 3.84 $2.66 1.44
2011-04-30 3.99 $2.62 1.52
2011-01-31 4.96 $2.57 1.93
2010-10-31 4.31 $2.56 1.68
2010-07-31 4.60 $2.56 1.80
2010-04-30 5.97 $2.55 2.34
2010-01-31 4.74 $2.55 1.86
2009-10-31 5.51 $2.49 2.21
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.110B $0.118B
Enzo Biochem, Inc. develops, manufactures and markets health care products based on molecular biology and genetic engineering techniques, and also provides diagnostic services to the medical community. The business activities of the company are performed by one of the company's three wholly-owned subsidiaries--Enzo Diagnostics, Inc., Enzo Therapeutics, Inc., and Enzo Clinical Labs, Inc. The primary focus of the company's research is the development of products based on two technology platforms -- genetic modulation and immune modulation.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $162.107B 9.86
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.761B 16.99
Biohaven Pharmaceutical Holding (BHVN) United States $10.111B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.648B 0.00
Emergent Biosolutions (EBS) United States $1.770B 7.57
Arcus Biosciences (RCUS) United States $1.376B 34.89
Myovant Sciences (MYOV) United Kingdom $1.033B 0.00
Zymeworks (ZYME) Canada $0.397B 0.00
Gelesis Holdings (GLS) United States $0.345B 0.00
Ambrx Biopharma (AMAM) United States $0.157B 0.00
SQZ Biotechnologies (SQZ) United States $0.100B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00